Companies

Valneva has issued almost 16 million new shares. Image courtesy of Valneva

Companies May 1, 2026

Valneva shores up balance sheet after mixed trial results

Vaccine specialist Valneva has sold new shares worth €84 million as it moves to strengthen its balance sheet in the wake of mixed results for…

Strong performance in its long-acting HIV preventable has helped GlaxoSmithKline to raise its profit forecasts

GSK’s Q3 results buoyed by long-acting HIV jab

Sanofi Global Health Unit says 1 mln reached since 2021

At the Seventh Replenishment summit in 2022, the US committed $6 billion, out of a record $15 billion raised.

Viiv/GSK pledge $8 mln ahead of Global Fund summit

Two private equity firms bidding for Bavarian Nordic have increased their offer for the Danish maker of vaccines for mpox, cholera and chikungunya.

Suitors up price for Bavarian Nordic

Lilly has announced a tie-up with the WHO Foundation to financially support the aims of the WHO’s global dementia action plan.

Lilly tight-lipped over WHO Foundation dementia deal

EU approves Bavarian Nordic takeover bid

Bavarian Nordic’s troubled takeover bid gets EU clearance

A vaccination centre in India

Valneva extends loans after chikungunya jab concerns